$辉瑞(PFE)$ C.Q. Pharmaceutical's (SHE:000950) unit, Chongqing Yaoyou Pharmaceutical, granted Pfizer exclusive rights to develop, produce and market oral small molecule glucagon-like peptide-1 receptor agonists and products containing this active ingredient, such as YP05002, according to a Shenzhen bourse filing on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
